Merck & Co Inc MRK:NYSE

Earnings Announcement Next Earnings date is expected on 02/03/2022
Last Price$79.14NYSE Previous Close - Last Trade as of 7:00PM ET 1/26/22

Today's Change-0.32(0.40%)
Bid (Size)$79.00 (1)
Ask (Size)$79.35 (3)
Day Low / High$78.73 - 80.34
Volume13.0 M

View Pharmaceuticals: Major IndustryPeer Comparison as of 01/26/2022


Merck & Co Inc ( NYSE )

Price: $79.14
Change: -0.32 (0.40%)
Volume: 13.0 M
7:00PM ET 1/26/2022

Eli Lilly and Co ( NYSE )

Price: $237.86
Change: -1.60 (0.67%)
Volume: 2.9 M
7:00PM ET 1/26/2022

Abbvie Inc ( NYSE )

Price: $134.23
Change: +1.14 (0.86%)
Volume: 8.0 M
7:00PM ET 1/26/2022

Bristol-Myers Squibb Co ( NYSE )

Price: $62.24
Change: -0.22 (0.35%)
Volume: 13.7 M
7:00PM ET 1/26/2022

Pfizer Inc ( NYSE )

Price: $52.61
Change: +0.07 (0.13%)
Volume: 39.6 M
7:00PM ET 1/26/2022

Read more news Recent News

Vaccinex Says Two Patients Showed Complete Response in Study of Combo Drug Treatment for Head and Neck Cancer
9:13AM ET 1/26/2022 MT Newswires

Vaccinex (VCNX) said Wednesday that two out of three patients enrolled in a phase 1b study of a combination drug treatment for recurrent or metastatic head...

--Merck & Co. Declares Q2 Dividend of $0.69, Payable April 7 to Shareholders of Record March 15
2:13PM ET 1/25/2022 MT Newswires

Price: 79.34, Change: +0.51, Percent Change: +0.65 ...

Market Chatter: EU Drug Regulator Reportedly Will Decide on Approval of Pfizer's COVID-19 Pill by End of January
11:05AM ET 1/24/2022 MT Newswires

The European Union's drug regulator is expected to issue a decision on Pfizer's (PFE) application for its COVID-19 pill at the end of January, before a...

FDA Declines to Approve Merck's Investigational Cough Treatment Gefapixant
7:22AM ET 1/24/2022 MT Newswires

Merck & Company (MRK) on Monday said that the US Food and Drug Administration has issued a complete response letter for gefapixant, the company's...

View all Commentary and Analysis

Merck (MRK) Dips More Than Broader Markets: What You Should Know
5:45PM ET 1/26/2022 Zacks

Merck (MRK) closed the most recent trading day at $79.14, moving -0.4% from the previous trading...

Tracking Kahn Brothers Portfolio - Q4 2021 Update
9:59PM ET 1/25/2022 Seeking Alpha

Merck & Co (MRK) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
2:26PM ET 1/24/2022 Seeking Alpha

Week 4 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge
12:36PM ET 1/24/2022 Seeking Alpha

Company Profile

Business DescriptionMerck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ. View company web site for more details
Address2000 Galloping Hill Road
Kenilworth, New Jersey 07033
Number of Employees69,000
Recent SEC Filing01/04/20224
President, Chief Executive Officer & DirectorRobert M. Davis
Chief Financial Officer & Executive Vice PresidentCaroline A. Litchfield
Vice President-R&D IT CIOSandy Tremps
Chief Information & Digital OfficerDave Williams

Company Highlights

Price Open$79.39
Previous Close$79.46
52 Week Range$70.89 - 91.40
Market Capitalization$199.9 B
Shares Outstanding2.5 B
SectorHealth Technology
IndustryPharmaceuticals: Major
Current Dividend / Yield$0.69 / 3.47%
Dividend Ex-Date12/14/2021
Dividend Pay-Date01/07/2022
Dividend Yield 5 Year Average2.87%
Next Earnings Announcement02/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings28.26
Earnings per Share$3.82
Beta vs. S&P 500N/A
Revenue$42.4 B
Net Profit Margin14.04%
Return on Equity22.63%

Analyst Ratings as of 01/19/2022

Consensus RecommendationConsensus Icon
Powered by Factset